Familial Alzheimer's Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-beta Protein Precursor Generated by Beta-secretase Cleavage

Overview

Journal Curr Alzheimer Res

Publisher Bentham Science Publishers

Specialty Neurology

Date 2010 Mar 9

PMID 20205669

Citations 13

Authors

Can Zhang

Andrew Browne

Doo Yeon Kim

Rudolph E Tanzi

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is an insidious and progressive disease with a genetically complex and heterogenous etiology. More than 200 fully penetrant mutations in the amyloid beta-protein precursor (APP), presenilin 1 (or PSEN1), and presenilin 2 (PSEN2) have been linked to early-onset familial AD (FAD). 177 PSEN1 FAD mutations have been identified so far and account for more than approximately 80% of all FAD mutations. All PSEN1 FAD mutations can increase the Abeta42:Abeta40 ratio with seemingly different and incompletely understood mechanisms. A recent study has shown that the 286 amino acid N-terminal fragment of APP (N-APP), a proteolytic product of beta-secretase-derived secreted form of APP (sAPPbeta), could bind the death receptor, DR6, and lead to neurodegeneration. Here we asked whether PSEN1 FAD mutations lead to neurodegeneration by modulating sAPPbeta levels. All four different PSEN1 FAD mutations tested (in three mammalian cell lines) did not alter sAPPbeta levels. Therefore PS1 mutations do not appear to contribute to AD pathogenesis via altered production of sAPPbeta.

Citing Articles

PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease.

Kumar M, Sharma A, Datusalia A, Khatik G Med Chem. 2024; 20(8):781-798.

PMID: 38726789 DOI: 10.2174/0115734064295063240422100615.

Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer's disease-related neuropathology in cell models.

Zhang S, Bai P, Lei D, Liang Y, Zhen S, Bakiasi G J Biol Chem. 2022; 298(4):101794.

PMID: 35248531 PMC: 8958546. DOI: 10.1016/j.jbc.2022.101794.

: A Model System for Neurological Disorders.

Storey C, Williams R, Fisher P, Annesley S Cells. 2022; 11(3).

PMID: 35159273 PMC: 8833889. DOI: 10.3390/cells11030463.

All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration.

Argueti-Ostrovsky S, Alfahel L, Kahn J, Israelson A Cells. 2021; 10(9).

PMID: 34572087 PMC: 8468417. DOI: 10.3390/cells10092438.

Brain-derived neurotrophic factor increases cell number of neural progenitor cells derived from human induced pluripotent stem cells.

Pansri P, Phanthong P, Suthprasertporn N, Kitiyanant Y, Tubsuwan A, Dinnyes A PeerJ. 2021; 9:e11388.

PMID: 34026357 PMC: 8123227. DOI: 10.7717/peerj.11388.

References

Xia W, Ostaszewski B, Kimberly W, Rahmati T, Moore C, Wolfe M . FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex. Neurobiol Dis. 2000; 7(6 Pt B):673-81. DOI: 10.1006/nbdi.2000.0322. View

Tanzi R, Gusella J, Watkins P, BRUNS G, St George-Hyslop P, Van Keuren M . Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987; 235(4791):880-4. DOI: 10.1126/science.2949367. View

Kim T, Pettingell W, Jung Y, Kovacs D, Tanzi R . Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science. 1997; 277(5324):373-6. DOI: 10.1126/science.277.5324.373. View

Tanzi R, Bertram L . Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005; 120(4):545-55. DOI: 10.1016/j.cell.2005.02.008. View

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

Zhang J, Kang D, Xia W, Okochi M, Mori H, Selkoe D . Subcellular distribution and turnover of presenilins in transfected cells. J Biol Chem. 1998; 273(20):12436-42. DOI: 10.1074/jbc.273.20.12436. View

Xie Z, Romano D, Kovacs D, Tanzi R . Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation. J Biol Chem. 2004; 279(33):34130-7. DOI: 10.1074/jbc.M401094200. View

Gandy S, Naslund J, Nordstedt C . Alzheimer's disease. Molecular consequences of presenilin-1 mutation. Nature. 2001; 411(6838):654-6. DOI: 10.1038/35079682. View

Hiltunen M, Lu A, Thomas A, Romano D, Kim M, Jones P . Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. J Biol Chem. 2006; 281(43):32240-53. DOI: 10.1074/jbc.M603106200. View

10.

Zhang C, Saunders A . Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer's disease. Discov Med. 2007; 7(39):113-7. View

11.

Nikolaev A, McLaughlin T, OLeary D, Tessier-Lavigne M . APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009; 457(7232):981-9. PMC: 2677572. DOI: 10.1038/nature07767. View

12.

Huttunen H, Guenette S, Peach C, Greco C, Xia W, Kim D . HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. J Biol Chem. 2007; 282(38):28285-95. DOI: 10.1074/jbc.M702951200. View

13.

Xia W, Zhang J, Ostaszewski B, Kimberly W, Seubert P, Koo E . Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry. 1998; 37(47):16465-71. DOI: 10.1021/bi9816195. View

14.

Bertram L, Tanzi R . Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. 2008; 9(10):768-78. DOI: 10.1038/nrn2494. View

15.

Kovacs D, Mancini R, Henderson J, Na S, Schmidt S, Kim T . Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer's disease mutations in human neuroglioma cells. J Neurochem. 1999; 73(6):2278-85. DOI: 10.1046/j.1471-4159.1999.0732278.x. View

16.

Xie Z, Romano D, Tanzi R . Effects of RNAi-mediated silencing of PEN-2, APH-1a, and nicastrin on wild-type vs FAD mutant forms of presenilin 1. J Mol Neurosci. 2005; 25(1):67-77. DOI: 10.1385/JMN:25:1:067. View

17.

Zhang C, Khandelwal P, Chakraborty R, Cuellar T, Sarangi S, Patel S . An AICD-based functional screen to identify APP metabolism regulators. Mol Neurodegener. 2007; 2:15. PMC: 2071909. DOI: 10.1186/1750-1326-2-15. View

18.

Xie Z, Romano D, Tanzi R . RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. J Biol Chem. 2005; 280(15):15413-21. DOI: 10.1074/jbc.M414353200. View

19.

Russo C, Schettini G, Saido T, Hulette C, Lippa C, Lannfelt L . Presenilin-1 mutations in Alzheimer's disease. Nature. 2000; 405(6786):531-2. DOI: 10.1038/35014735. View

20.

Page R, Baumann K, Tomioka M, Perez-Revuelta B, Fukumori A, Jacobsen H . Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem. 2007; 283(2):677-83. DOI: 10.1074/jbc.M708754200. View